Key points are not available for this paper at this time.
Lenacapavir is widely recognised as a major scientific advance in HIV prevention. Lenacapavir is a twice-yearly injectable prophylaxis that addresses barriers to daily oral medication and has shown high efficacy in clinical trials. Enthusiasm regarding lenacapavir within global policy discussions reflects genuine scientific progress and a commitment to developing effective prevention beyond treatment. This excitement is understandable. However, African countries are facing a lenacapavir roll-out, while HIV epidemics remain incompletely controlled, with approximately 5·8 million people living with HIV not virally suppressed and health systems facing increasing fiscal and operational pressure.
Reuben Granich (Thu,) studied this question.